Leerink Partners Reiterates Outperform Rating on Veracyte, Inc (VCYT)

Leerink Partners analyst Puneet Souda reiterated an Outperform rating and $50.00 price target on Veracyte, Inc (NASDAQ: VCYT).

The analyst comments "Bottom Line: VCYT's Decipher volumes landed in line to expectations and VCYT initiated its 2026 guide at 2% above cons. Though we believe that investors will find some comfort with the conservative guide, we expect some questions on Decipher's growth outlook in 2026 with in-line 4Q volumes. Decipher volumes grew 21% y/y but came in-line (27.2k vs LPe: 26.3k, cons: 27.2k. FY26 guidance of $570M - $582M (10% - 13% growth) compares favorably to LPe: $569, cons: $564M (midpoint 2% above cons). Afirma modestly beat (18.3 vs LPe: 18.3k, cons: 17.6k), and total revs of $138M - $140M were ahead (LPe: $133M, cons: $132M). VCYT also disclosed testing revs guidance ($559M - $569M; does not include Prosigna launch) and 4Q25 testing revs of $134M - $136M. FY25 EBITDA margins are expected to be above 25% and FY26 EBITDA margins are expected to be 25%. We expect the main focus in VCYT mgmt. meetings this week will be Decipher momentum in 2026, breaking down the various drivers for guidance, and understanding the expected Decipher contribution for the year."

For an analyst ratings summary and ratings history on Veracyte, Inc click here. For more ratings news on Veracyte, Inc click here.

Shares of Veracyte, Inc closed at $42.04 yesterday.

You May Also Be Interested In